EXCLUSIVE: Virax Biolabs Launches RSV/Flu/COVID-19 Combo Rapid Test Kit In Europe

Virax Biolabs Group Ltd VRAX has launched the RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit in the European Union.

What Happened: The test kits are used at home and in point-of-care settings to accurately identify infections related to a respiratory syncytial virus (RSV), influenza, and COVID-19, with results typically available in 15 minutes.

The specialized diagnostic kits can be found by contacting the company's sales representatives.

Related: EXCLUSIVE: Newly Listed Virax Biolabs Launches Monkeypox Antigen Rapid Test.

The RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit is an in vitro immunochromatographic assay for the qualitative and differential detection of nucleocapsid protein antigen from influenza A, influenza B, RSV, and COVID-19 in nasal swab specimens from individuals with or without symptoms.

Why It Matters: Chairman & CEO James Foster commented, "the major industrialized economies are facing a triple threat this year through higher levels of RSV and influenza infections on top of the ongoing COVID-19 pandemic. Giving people the ability to test for all three at home will improve the ability of healthcare systems to manage these infections in a timely manner."

Price Action: VRAX shares are down 2.98% at $1.63 during the premarket session on the last check Thursday.

Market News and Data brought to you by Benzinga APIs
Posted In: NewsPenny StocksHealth CareMarket-Moving ExclusivesExclusivesGeneralCOVID-19 CoronavirusDiagnostics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!